New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07545122
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a protein called Nectin-4 on their surface. The study will first find a safe dose and then check if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT-202 (a bispecific antibody that targets Nectin-4 on cancer cells)
- What this could lead to
- If successful, this could lead to a new treatment option for people with certain advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1) trial, so the drug may not be safe or effective. Side effects could be severe, and it is only tested in a small number of people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Calvary Mater Hospital Newcastle
Newcastle, Queensland, Australia
-
Linear Clinical Research
Perth, Western Australia, Australia
-
Tasman Oncology Research
Gold Coast, Queensland, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?